MD Anderson and the Rare Cancer Research Foundation launch collaboration to accelerate the development of treatments for rare cancers
The University of Texas MD Anderson Cancer Center and the Rare Cancer Research Foundation today announced the launch of a collaboration designed to accelerate the development of new treatments for rare cancers by empowering all patients in the United States to contribute tumor samples directly to MD Anderson for translational research efforts.
This initiative is designed to overcome a major obstacle that has long prevented significant...
MD Anderson and Siemens Healthineers collaborating to enable consistent clinical implementation of quantitative MRI
The University of Texas MD Anderson Cancer Center and Siemens Healthineers today announced the collaborative development of a global education...
MD Anderson and BostonGene announce strategic alliance to advance personalized cancer diagnostics and treatments
The University of Texas MD Anderson Cancer Center and BostonGene Corporation today announced a strategic alliance to advance the development...
MD Anderson celebrates World Cancer Research Day, progress made to end cancer through research
The University of Texas MD Anderson Cancer Center is proud to support World Cancer Research Day, Sept. 24, and its efforts to promote cancer research as a driving force behind progress in cancer prevention, early detection, treatment and survivorship.
World Cancer Research Day, a global collaboration launched in 2016 by 10 institutions, is focusing this year on the theme “Cancer Research Works: Driving Progress Together.” More...
MD Anderson Research Highlights: ESMO 2021 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and...
Link between inflammation and pancreatic cancer development uncovered
HOUSTON ― A new discovery from researchers at The University of Texas MD Anderson Cancer Center has clarified the long-established connection...
MD Anderson and SNIPR BIOME collaborate to advance next-generation CRISPR microbiome therapeutics
The University of Texas MD Anderson Cancer Center and SNIPR BIOME today announced a strategic collaboration to advance new CRISPR-based microbiome...
MD Anderson and Bellicum announce additional license agreement for use of CaspaCIDe® safety switch
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement...